Illumina Just Dissed the European Commission. This Analyst Thinks That Was a Risky Move
In September 2020, genetic testing equipment manufacturer Illumina (ILMN) announced that it would buy back Grail, a liquid biopsy company that it had previously spun off four years prior. The price Illumina would pay — $8 billion in cash and stock — raised…
